These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells. Ozkan T; Hekmatshoar Y; Pamuk H; Ozcan M; Yaman G; Yagiz GC; Akdemir C; Sunguroglu A Mol Biol Rep; 2021 Feb; 48(2):1625-1631. PubMed ID: 33515349 [TBL] [Abstract][Full Text] [Related]
7. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia]. Tsubaki M Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658 [TBL] [Abstract][Full Text] [Related]
8. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia. Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353 [TBL] [Abstract][Full Text] [Related]
9. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells. Yamakawa Y; Hamada A; Uchida T; Sato D; Yuki M; Hayashi M; Kawaguchi T; Saito H Biol Pharm Bull; 2014; 37(8):1330-5. PubMed ID: 25087954 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of protein kinase CK2 by CX-5011 counteracts imatinib-resistance preventing rpS6 phosphorylation in chronic myeloid leukaemia cells: new combined therapeutic strategies. Salizzato V; Borgo C; Cesaro L; Pinna LA; Donella-Deana A Oncotarget; 2016 Apr; 7(14):18204-18. PubMed ID: 26919095 [TBL] [Abstract][Full Text] [Related]
11. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells. Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755 [TBL] [Abstract][Full Text] [Related]
12. JKST6, a novel multikinase modulator of the BCR-ABL1/STAT5 signaling pathway that potentiates direct BCR-ABL1 inhibition and overcomes imatinib resistance in chronic myelogenous leukemia. Aranda-Tavío H; Recio C; Martín-Acosta P; Guerra-Rodríguez M; Brito-Casillas Y; Blanco R; Junco V; León J; Montero JC; Gandullo-Sánchez L; McNaughton-Smith G; Zapata JM; Pandiella A; Amesty A; Estévez-Braun A; Fernández-Pérez L; Guerra B Biomed Pharmacother; 2021 Dec; 144():112330. PubMed ID: 34673425 [TBL] [Abstract][Full Text] [Related]
13. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells. Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884 [TBL] [Abstract][Full Text] [Related]
14. Overexpression of Deng Y; Li X; Feng J; Zhang X Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564 [TBL] [Abstract][Full Text] [Related]
15. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML). Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133 [TBL] [Abstract][Full Text] [Related]
16. Emodin Inhibits Resistance to Imatinib by Downregulation of Bcr-Abl and STAT5 and Allosteric Inhibition in Chronic Myeloid Leukemia Cells. Wang XY; Sun GB; Wang YJ; Yan F Biol Pharm Bull; 2020; 43(10):1526-1533. PubMed ID: 32999163 [TBL] [Abstract][Full Text] [Related]
17. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib. Yandim MK; Ceylan C; Elmas E; Baran Y Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734 [TBL] [Abstract][Full Text] [Related]
18. Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia. Yin L; Xu J; Wu W; Niu M; Li Z; Zhu F; Xu K Hematology; 2023 Dec; 28(1):2224625. PubMed ID: 37345979 [TBL] [Abstract][Full Text] [Related]
19. Targeting HSPA8 inhibits proliferation via downregulating BCR-ABL and enhances chemosensitivity in imatinib-resistant chronic myeloid leukemia cells. Liu Z; Zheng W; Liu Y; Zhou B; Zhang Y; Wang F Exp Cell Res; 2021 Aug; 405(2):112708. PubMed ID: 34157313 [TBL] [Abstract][Full Text] [Related]
20. Aberrant signalling by protein kinase CK2 in imatinib-resistant chronic myeloid leukaemia cells: biochemical evidence and therapeutic perspectives. Borgo C; Cesaro L; Salizzato V; Ruzzene M; Massimino ML; Pinna LA; Donella-Deana A Mol Oncol; 2013 Dec; 7(6):1103-15. PubMed ID: 24012109 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]